European Footprint

Lilly is a biopharmaceutical company with over 34,000 employees worldwide, including more than 9,000 in Europe. Founded over 140 years ago and established in Europe in 1934, our pioneering medical breakthroughs through the years include the first commercially available human insulin and the polio vaccine.

In addition to commercial activities that span the whole of Europe, we have a considerable R&D and manufacturing presence located across four countries in Europe, as well as nine beyond.

R&D and manufacturing sites in Europe

  • Alcobendas, Spain

    • Inaugurated in 1968, Alcobendas is both a major R&D and manufacturing site.

    • Exports €1.4b worth of products to 125 countries across the world.

    • Researchers active in oncology, endocrinology and neuroscience.

    • Lilly invests +€52m in R&D in Spain annually, making Alcobendas the leading pharmaceutical research private centre in Spain.

  • Fegersheim, France

    • Opened in 1967, Fegersheim is a major global manufacturing site, with production capacity of 167 million units per year.

    • Specialized in injectable treatments in the following therapeutic areas: endocrinology, rheumatology and oncology.

    • 97% of Fegersheim’s production is exported to more than 100 destinations across the world.

  • Kinsale, Ireland

    • Production commenced at Lilly’s manufacturing site at Kinsale in 1981.

    • The site has grown to become a large manufacturing campus that now makes active ingredients for Lilly medicines using both chemical synthesis and biotechnology manufacturing platforms.

    • The Kinsale mission is to support the commercialization, manufacture and supply of many new medicines in Lilly's portfolio across therapeutic areas such as oncology, immunology, diabetes and pain.

    • Over the last decade, Kinsale has fostered closer collaboration with Lilly research colleagues involved in late phase product development and process optimization. This effort is aimed at creating a partnership between the Lilly R&D and Manufacturing components and to improve speed to market for Lilly’s newest medicines.

  • Sesto Fiorentino, Italy

    • Lilly Italy was founded back in 1959 at Sesto Fiorentino near Florence.

    • The Sesto site manufactures more than 50% of Lilly’s insulin worldwide production.

    • The site exports 98% of its production to 70 European and non-European countries.

    • Lilly invests +€18m in R&D in Italy annually, with researchers at Sesto and a further site in Catania, Sicily, active in diabetes, oncology and immunology.